Department of Radiology, Liver Imaging Group, University of California San Diego, San Diego, CA, USA.
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Br J Radiol. 2021 May 1;94(1121):20201377. doi: 10.1259/bjr.20201377. Epub 2021 Feb 26.
Chronic liver disease (CLD) has rapidly increased in prevalence over the past two decades, resulting in significant morbidity and mortality worldwide. Historically, the clinical gold standard for diagnosis, assessment of severity, and longitudinal monitoring of CLD has been liver biopsy with histological analysis, but this approach has limitations that may make it suboptimal for clinical and research settings. Magnetic resonance (MR)-based biomarkers can overcome the limitations by allowing accurate, precise, and quantitative assessment of key components of CLD without the risk of invasive procedures. This review briefly describes the limitations associated with liver biopsy and the need for non-invasive biomarkers. It then discusses the current state-of-the-art for MRI-based biomarkers of liver iron, fat, and fibrosis, and inflammation.
在过去的二十年中,慢性肝病(CLD)的患病率迅速上升,在全球范围内导致了显著的发病率和死亡率。从历史上看,肝活检结合组织学分析一直是 CLD 的诊断、严重程度评估和纵向监测的临床金标准,但这种方法存在局限性,使其在临床和研究环境中可能不是最佳选择。基于磁共振(MR)的生物标志物可以通过允许对 CLD 的关键成分进行准确、精确和定量的评估,而无需进行有创操作,从而克服这些局限性。本综述简要描述了肝活检的局限性以及对非侵入性生物标志物的需求。然后讨论了基于 MRI 的肝铁、脂肪和纤维化以及炎症生物标志物的最新现状。